These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 11735262

  • 1. p38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning.
    Marais E, Genade S, Strijdom H, Moolman JA, Lochner A.
    J Mol Cell Cardiol; 2001 Dec; 33(12):2157-77. PubMed ID: 11735262
    [Abstract] [Full Text] [Related]

  • 2. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion.
    Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A.
    J Mol Cell Cardiol; 2001 Apr; 33(4):769-78. PubMed ID: 11273729
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning.
    Marais E, Genade S, Salie R, Huisamen B, Maritz S, Moolman JA, Lochner A.
    Basic Res Cardiol; 2005 Jan; 100(1):35-47. PubMed ID: 15526116
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Kinases and phosphatases in ischaemic preconditioning: a re-evaluation.
    Fan WJ, van Vuuren D, Genade S, Lochner A.
    Basic Res Cardiol; 2010 Jul; 105(4):495-511. PubMed ID: 20127248
    [Abstract] [Full Text] [Related]

  • 7. Comparison between ischaemic and anisomycin-induced preconditioning: role of p38 MAPK.
    Lochner A, Genade S, Hattingh S, Marais E, Huisamen B, Moolman JA.
    Cardiovasc Drugs Ther; 2003 May; 17(3):217-30. PubMed ID: 14574080
    [Abstract] [Full Text] [Related]

  • 8. Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning.
    Lochner A, Marais E, Genade S, Huisamen B, du Toit EF, Moolman JA.
    Cardiovasc J Afr; 2009 May; 20(1):43-51. PubMed ID: 19287816
    [Abstract] [Full Text] [Related]

  • 9. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical.
    Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM.
    Basic Res Cardiol; 2000 Dec; 95(6):472-8. PubMed ID: 11192368
    [Abstract] [Full Text] [Related]

  • 10. The role of β-adrenergic receptors in the cardioprotective effects of beta-preconditioning (βPC).
    Salie R, Moolman JA, Lochner A.
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):31-46. PubMed ID: 21225332
    [Abstract] [Full Text] [Related]

  • 11. Role of p38-mitogen-activated protein kinase in ischaemic preconditioning in rat heart.
    Bell JR, Eaton P, Shattock MJ.
    Clin Exp Pharmacol Physiol; 2008 Feb; 35(2):126-34. PubMed ID: 17892505
    [Abstract] [Full Text] [Related]

  • 12. Thyroid hormone and cardioprotection: study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart.
    Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV.
    Mol Cell Biochem; 2003 Jan; 242(1-2):173-80. PubMed ID: 12619880
    [Abstract] [Full Text] [Related]

  • 13. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart.
    Weinbrenner C, Liu GS, Cohen MV, Downey JM.
    J Mol Cell Cardiol; 1997 Sep; 29(9):2383-91. PubMed ID: 9299362
    [Abstract] [Full Text] [Related]

  • 14. The significance of the washout period in preconditioning.
    Salie R, Lochner A, Loubser DJ.
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28118517
    [Abstract] [Full Text] [Related]

  • 15. Opioid receptor stimulation acts as mediator of protection in ischaemic preconditioning.
    Genade S, Moolman JA, Lochner A.
    Cardiovasc J S Afr; 2001 Jun; 12(1):8-16. PubMed ID: 11447487
    [Abstract] [Full Text] [Related]

  • 16. The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation.
    Salie R, Moolman JA, Lochner A.
    Basic Res Cardiol; 2012 Sep; 107(5):281. PubMed ID: 22797560
    [Abstract] [Full Text] [Related]

  • 17. Myocardial adenosine does not correlate with the protection mediated by ischaemic or pharmacological preconditioning in rat heart.
    Vasara E, Katharou I, Lazou A.
    Clin Exp Pharmacol Physiol; 2003 Sep; 30(5-6):350-6. PubMed ID: 12859425
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling.
    Das S, Tosaki A, Bagchi D, Maulik N, Das DK.
    J Pharmacol Exp Ther; 2006 Jun; 317(3):980-8. PubMed ID: 16525036
    [Abstract] [Full Text] [Related]

  • 19. Effects of inhibition of myocardial extracellular-responsive kinase and P38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia.
    Clanachan AS, Jaswal JS, Gandhi M, Bottorff DA, Coughlin J, Finegan BA, Stone JC.
    Transplantation; 2003 Jan 27; 75(2):173-80. PubMed ID: 12548118
    [Abstract] [Full Text] [Related]

  • 20. p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart.
    Gysembergh A, Simkhovich BZ, Kloner RA, Przyklenk K.
    J Mol Cell Cardiol; 2001 Apr 27; 33(4):681-90. PubMed ID: 11273721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.